Ads
related to: saia workday portal patient access solutions genentech group
Search results
Results From The WOW.Com Content Network
Workday, Inc., is an American on‑demand (cloud-based) financial management, human capital management, and student information system software vendor. Workday was founded by David Duffield, founder and former CEO of ERP company PeopleSoft, along with former PeopleSoft chief strategist Aneel Bhusri, following Oracle's acquisition of PeopleSoft in 2005.
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
The major shortcoming of most patient portals is their linkage to a single health organization. If a patient uses more than one organization for healthcare, the patient typically needs to log on to each organization's portal to access information. This results in a fragmented view of individual patient data. [3]
Saia acquired Robart Transportation (and subsidiary The RL Services Group) in 2012 for approximately $7.8 million. Robart, founded in 1981 in Duluth, Georgia , was a non-asset truckload and brokerage service provider while The RL Services Group focused on supply chain, logistics, data mining, and operations analysis and related services.
Alight Solutions is an information technology and consulting company based in Chicago, Illinois. The company provides cloud-based digital business and human capital service solutions [ clarification needed ] ; particularly within the areas of wealth and health resources. [ 1 ]
The Access Group is a business software company headquartered in Loughborough, England. It was founded in 1991, and currently has more than 7,500 employees. [ 1 ] It provides business management software to over 100,000 organisations across the UK, Ireland, US and Asia Pacific. [ 2 ]
Kleiner and Perkins provided $100,000 on the May closing, and acquired 20,000 shares of preferred stock from Genentech. [6] Swanson was made the president and treasurer of Genentech, and received a $2,500 per month salary, along with 25,000 shares. [6] This marked the end of Swanson's unemployment, and the beginning of his career at Genentech ...
From 2017 to 2018, he was the CEO of Genentech. [6] While at Genentech, he developed its immunology and ophthalmology divisions, managed the sales of Rituxan, Raptiva, and Xolair, and directed Roche's late-stage portfolio committee for nearly four years, where he was responsible for determining late-stage clinical trial advancements. [6]